






**COUPLING PROTEINS TO A MODIFIED POLYSACCHARIDE****Publication number:** DE10209821 (A1)**Publication date:** 2003-09-25**Inventor(s):** HEMBERGER JUERGEN [DE]; ORLANDO MICHELE [DE]**Applicant(s):** BIOTECHNOLOGIE GES MITTELHESSE [DE]**Classification:**

- **international:** C12N9/00; A61K35/58; A61K35/66; A61K38/00; A61K38/16; A61K38/21; A61K38/22; A61K38/26; A61K38/27; A61K38/28; A61K38/44; A61K39/00; A61K39/395; A61K47/48; A61P37/02; C07K1/10; C08B31/00; C08B31/18; C08H1/00; C12N9/00; A61K35/56; A61K35/66; A61K38/00; A61K38/16; A61K38/21; A61K38/22; A61K38/26; A61K38/27; A61K38/28; A61K38/43; A61K39/00; A61K39/395; A61K47/48; A61P37/00; C07K1/00; C08B31/00; C08H1/00; (IPC1-7): C07K2/00; A61K38/43




- **European:** A61K47/48K8; C08B31/00; C08B31/18; C08B31/18B; C08H1/00

**Application number:** DE20021009821 20020306**Priority number(s):** DE20021009821 20020306**Also published as:**

 WO03074087 (A1)  
 US2005181985 (A1)  
 CN1638808 (A)  
 AU2003215617 (A1)  
 CA2478478 (A1)

more &gt;&gt;

**Cited documents:**

 DE19628705 (A1)  
 DE10112825 (A1)  
 US5218108 (A)

Abstract not available for DE 10209821 (A1)

Abstract of corresponding document: **WO 03074087 (A1)**

The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond.; The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.

.....  
 Data supplied from the **esp@cenet** database — Worldwide